Specifics:

 

Treatment Type:

Dual 5-alpha Reductase Inhibitor

Testing Progress:

Approved for Benign Prostatic Hyperplasia (BPH)
Phase III trials for hair loss believed resumed – Supplemental New Drug Application for Hair loss may be submitted to FDA

Clinical Results:

Much greater and longer inhibition of DHT than Propecia in early testing.

Notes:

The big question will be is it better than Propecia and whether side effects will be greater or more serious. Currently approved form will be a 0.5 mg soft gel.

---